Plasticity of the human IgM repertoire in response to long‐term spaceflight2021-02-11T20:09:45-08:00October 13th, 2020|Read more
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy2021-02-11T20:11:02-08:00October 8th, 2020|Read more
Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype2021-02-11T20:13:51-08:00August 27th, 2020|Read more
Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment2021-02-11T20:26:38-08:00July 22nd, 2020|Read more
Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides2021-02-11T21:43:52-08:00June 8th, 2020|Read more
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML2026-10-26T12:21:04-07:00April 28th, 2017|Read more
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies2026-10-21T21:31:07-07:00March 28th, 2017|Read more
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software2021-02-26T19:13:58-08:00February 28th, 2017|Read more
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits2021-02-26T19:14:04-08:00February 14th, 2017|Read more
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits2021-02-26T19:14:11-08:00January 31st, 2017|Read more
